Table 1

Demographic and disease factors at baseline

Placebo+MTX
(n=63)*
TCZ+MTX
(n=69)
Female, n (%)47 (75)57 (83)
Age, years57.0 (50.0–64.0)57.0 (49.0–62.0)
Weight, kg82.0 (65.0–92.1)77.4 (67.0–86.5)
BMI, kg/m2, median (range)29.2 (18.5–49.6)29.2 (19.4–57.3)
Current smoker, n (%)14 (22)19 (28)
History of diabetes, n (%)4 (6)6 (9)
Duration of RA, years6.8 (2.4–9.9)7.0 (2.0–16.2)
DAS286.6 (5.8–7.3)6.8 (5.9–7.4)
CRP, mg/dL0.88 (0.39–1.86)0.94 (0.52–2.65)
Statin use, n (%)10 (16)10 (14)
Previous aTNF, n (%)19 (30)27 (39)
Oral steroid use, n (%)17 (27)20 (29)
Baseline MTX dose, mg/week15.0 (15.0–20.0)15.0 (15.0–20.0)
  • Data are presented as median (IQR) unless otherwise indicated.

  • *One patient randomly assigned to placebo+MTX actually received one dose of TCZ and was therefore included in the TCZ group for the safety analyses.

  • aTNF, anti-tumour necrosis factor α; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score at 28 joints; MTX, methotrexate; RA, rheumatoid arthritis; TCZ, tocilizumab.